Novel oral multifunctional antioxidant prevents noise-induced hearing loss and hair cell loss.

Administration, Oral Animals Antioxidants / administration & dosage Cell Line Disease Models, Animal Hair Cells, Auditory / drug effects Hearing / drug effects Hearing Loss, Noise-Induced / metabolism Oxidative Stress / drug effects Rats, Sprague-Dawley Reactive Nitrogen Species / metabolism Reactive Oxygen Species / metabolism
Hair cell loss Hearing loss Noise exposure Otoprotection Oxidative stress

Journal

Hearing research
ISSN: 1878-5891
Titre abrégé: Hear Res
Pays: Netherlands
ID NLM: 7900445

Informations de publication

Date de publication:
15 03 2020
Historique:
received: 19 09 2019
revised: 09 12 2019
accepted: 27 12 2019
pubmed: 17 1 2020
medline: 3 6 2021
entrez: 17 1 2020
Statut: ppublish

Résumé

Oxidative stress is a major contributor to noise-induced hearing loss, the most common cause of hearing loss among military personnel and young adults. HK-2 is a potent, orally-active, multifunctional, redox-modulating drug that has been shown to protect against a wide range of neurological disorders with no observed side effects. HK-2 protected cochlear HEI-OC1 cells against various forms of experimentally-induced oxidative stressors similar to those observed during and after intense noise exposure. The mechanisms by which HK-2 protects cells is twofold, first by its ability to reduce oxidative stress generated by free radicals, and second, by its ability to complex biologically active transition metals such as Fe

Identifiants

DOI: 10.1016/j.heares.2019.107880 PMID: 31945692 PMC: PMC7039757
pubmed: 31945692
pii: S0378-5955(19)30412-5
doi: 10.1016/j.heares.2019.107880
pmc: PMC7039757
mid: NIHMS1549709
pii:
doi:

Substances chimiques

Antioxidants 0
Reactive Nitrogen Species 0
Reactive Oxygen Species 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107880

Subventions

Organisme : NIDCD NIH HHS
ID : R43 DC016766
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Peter Kador is the President of Therapeutic Vision and hold the patent on HK-2. Dr. Salvi was the PI on a subaward on an NIH grant (1R43DC016766-01) to Therapeutic Vision to test the efficacy of HK-2.

Références

Clin Geriatr Med. 2015 Aug;31(3):355-66
pubmed: 26195095
Hear Res. 2014 Nov;317:1-8
pubmed: 25219503
Am J Pathol. 2009 May;174(5):1692-704
pubmed: 19349367
Hear Res. 2007 Apr;226(1-2):44-51
pubmed: 17030476
J Neurochem. 1995 Nov;65(5):2366-72
pubmed: 7595527
Acta Otolaryngol Suppl. 1995;519:87-92
pubmed: 7610900
Ear Hear. 2006 Feb;27(1):1-19
pubmed: 16446561
Audiol Neurootol. 1999 Sep-Oct;4(5):229-36
pubmed: 10436315
Mutat Res. 2011 May 18;722(1):69-77
pubmed: 21497204
Am J Ind Med. 2005 Dec;48(6):446-58
pubmed: 16299704
Antioxid Redox Signal. 2012 Oct 1;17(7):929-33
pubmed: 22524268
Am J Audiol. 2011 Jun;20(1):33-41
pubmed: 21474555
Curr Top Med Chem. 2015;15(2):170-8
pubmed: 25496272
MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):139-144
pubmed: 28182600
Acta Otolaryngol. 1986 Jul-Aug;102(1-2):20-6
pubmed: 3739689
Hear Res. 2006 Mar;213(1-2):118-29
pubmed: 16466871
Hear Res. 2007 Apr;226(1-2):104-13
pubmed: 17023129
Drug Discov Today. 2005 Oct 1;10(19):1291-8
pubmed: 16214673
Brain Res. 1999 Jan 9;815(2):317-25
pubmed: 9878807
J Vis Exp. 2016 Sep 03;(115):
pubmed: 27684094
Ear Hear. 2008 Jan;29(1):65-75
pubmed: 18091106
Noise Health. 1999;2(5):17-32
pubmed: 12689482
Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1821-1834
pubmed: 27858145
Noise Health. 2011 Nov-Dec;13(55):423-31
pubmed: 22122959
Neurosci Lett. 2005 Jun 3;380(3):234-8
pubmed: 15862892
Audiol Neurootol. 1999 Sep-Oct;4(5):219-28
pubmed: 10436314
Audiol Neurootol. 2003 Jul-Aug;8(4):177-89
pubmed: 12811000
Hear Res. 1996 Nov 1;101(1-2):14-22
pubmed: 8951429
Hear Res. 2007 Apr;226(1-2):114-25
pubmed: 17184943
Hear Res. 2007 Apr;226(1-2):22-43
pubmed: 17141991
J Audiol Otol. 2015 Dec;19(3):111-9
pubmed: 26771008
Hear Res. 1991 Feb;51(2):247-54
pubmed: 2032960
Hear Res. 2002 Feb;164(1-2):29-38
pubmed: 11950522
Eur Arch Otorhinolaryngol. 1995;252(8):504-8
pubmed: 8719596
Hear Res. 2015 May;323:40-50
pubmed: 25620313
Otolaryngol Head Neck Surg. 2011 Dec;145(6):999-1006
pubmed: 21750343
Int J Mol Sci. 2016 Aug 12;17(8):
pubmed: 27529239
Noise Health. 2005 Oct-Dec;7(29):24-30
pubmed: 17478966
Hear Res. 2018 Dec;370:209-216
pubmed: 30146226
Hear Res. 2005 Sep;207(1-2):35-42
pubmed: 15935579
Hear Res. 1998 Mar;117(1-2):31-8
pubmed: 9557976
Neuroscience. 2013 Dec 19;254:222-9
pubmed: 24060824
J Proteome Res. 2008 Aug;7(8):3516-24
pubmed: 18578524
Expert Opin Investig Drugs. 2017 Jan;26(1):85-96
pubmed: 27918210
Brain Res. 2003 Mar 21;966(2):265-73
pubmed: 12618349
Mol Pharmacol. 2017 Oct;92(4):375-388
pubmed: 28874607
J Occup Med Toxicol. 2010 Apr 28;5:11
pubmed: 20426871
J Med Chem. 2015 Nov 25;58(22):8796-805
pubmed: 26068053
Brain Res. 2004 Sep 3;1019(1-2):201-9
pubmed: 15306254
Ear Nose Throat J. 1997 Apr;76(4):248-50, 253-5
pubmed: 9127524
Hear Res. 2010 Jun 14;265(1-2):63-9
pubmed: 20214971
Hear Res. 2010 Aug;267(1-2):71-7
pubmed: 20430080
Mol Pharmacol. 2004 Oct;66(4):1043-53
pubmed: 15258257
J Alzheimers Dis. 2015;44(1):297-307
pubmed: 25227315
Hear Res. 2002 Feb;164(1-2):49-58
pubmed: 11950524

Auteurs

G D Chen (GD)

Center for Hearing and Deafness and Department of Communicative Disorders and Sciences, University at Buffalo, Buffalo, NY, 14214, USA.

D M Daszynski (DM)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

D Ding (D)

Center for Hearing and Deafness and Department of Communicative Disorders and Sciences, University at Buffalo, Buffalo, NY, 14214, USA.

H Jiang (H)

Center for Hearing and Deafness and Department of Communicative Disorders and Sciences, University at Buffalo, Buffalo, NY, 14214, USA.

T Woolman (T)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

K Blessing (K)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Therapeutic Vision, Inc., Elkhorn, NE, 68022, USA.

P F Kador (PF)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Therapeutic Vision, Inc., Elkhorn, NE, 68022, USA.

R Salvi (R)

Center for Hearing and Deafness and Department of Communicative Disorders and Sciences, University at Buffalo, Buffalo, NY, 14214, USA. Electronic address: salvi@buffalo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Eucaryotes › Animaux › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Agents protecteurs › Antioxydants › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Cellules › Neurones › Neurones afférents › Cellules réceptrices sensorielles › Mécanorécepteurs › Cellules neuroépithéliales › Cellules ciliées auditives › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sensation › Ouïe › Novel oral multifunctional antioxidant...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Troubles sensitifs › Troubles de l'audition › Perte d'audition › Surdité neurosensorielle › Surdité due au bruit › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Composés chimiques organiques › Composés nitrosés › Espèces réactives de l'azote › Novel oral multifunctional antioxidant...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Espèces réactives de l'oxygène › Novel oral multifunctional antioxidant...